Ever Supreme Bio Technology reported February revenue of NT$62.19 million (+3.35% YoY), supported by strong momentum in its CDMO business. For the full year 2025, revenue reached NT$1.018 billion with an **EPS of $4.88**. The board proposed a dividend of **NT$3.5 in cash and $0.5 in stock**.

• CAR-T Advancement: Its core allogeneic CAR-T product, CAR001, has entered the highest dose group (Cohort 5). Notably, a patient in Cohort 4 with Glioblastoma (GBM) showed an 80.02% reduction in tumor volume by Day 196 without standard-of-care steroids or chemotherapy, subsequently returning to work.
• Exosome Pipeline: * dEV-001: Targeted for Parkinson’s Disease, it successfully completed a U.S. FDA Pre-IND meeting in January 2026.
• EXO001: This in vivo CAR-T exosome platform has completed preclinical validation in various solid tumors (colorectal, pancreatic, and ovarian cancers). Research findings were published in the prestigious journal Advanced Science in February 2026.
• Global Licensing: Following the stabilization of its CDMO cash flow, the company is actively pursuing international licensing and strategic partnerships for its CAR-T and exosome platforms to unlock mid-to-long-term valuation.

Resource: 長聖2月營收6,219萬元、年增3.3% 擬配現金3.5元、股票股利0.5元